Carl Dambkowski, MD
Chief Medical Officer
Carl Dambkowski, M.D., is the Chief Medical Officer of Apogee Therapeutics. Prior to joining Apogee, Carl served as a strategic and clinical leader for multiple companies. He was part of the core teams that brought TRUSELTIQ (infigratinib) and NULIBRY (fosdenopterin) through approval at QED Therapeutics and Origin Biosciences. He also co-founded Novonate, a medical device company focused on building life-saving devices for neonates. Carl trained as a physician at Stanford, where he also received his B.A. The father of two and avid runner, he has run a sub 6-minute mile while pushing his daughter in a stroller.